| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Martin Weltman | |
| Angela Cropley | |||
| P2860 | cites work | Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions | Q28076505 |
| Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis | Q28248157 | ||
| Diagnosis and management of autoimmune hepatitis | Q34118165 | ||
| Treatment of autoimmune hepatitis: A review of current and evolving therapies | Q34149523 | ||
| Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared | Q34477263 | ||
| Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis | Q34494662 | ||
| Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people | Q34522550 | ||
| Autoimmune liver disease: overlap and outliers | Q34626237 | ||
| Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study | Q34825783 | ||
| Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy | Q37075975 | ||
| The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies | Q38122897 | ||
| Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly | Q38164847 | ||
| Autoimmune hepatitis: East meets west | Q38375866 | ||
| Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management | Q38568912 | ||
| A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis | Q39909124 | ||
| Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. | Q40441464 | ||
| Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy | Q40717973 | ||
| AIH: Which Alternative for Difficult-to-Treat Patients? | Q40881210 | ||
| Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. | Q41344505 | ||
| Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis | Q42285314 | ||
| Treatment response in patients with autoimmune hepatitis | Q42918487 | ||
| Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis | Q42989153 | ||
| Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis | Q43225448 | ||
| Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. | Q43244249 | ||
| Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis | Q43645960 | ||
| Rituximab for refractory autoimmune hepatitis: a case report | Q43854975 | ||
| Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. | Q45963125 | ||
| A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis | Q46808954 | ||
| Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. | Q50628941 | ||
| Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. | Q51035941 | ||
| Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. | Q53160616 | ||
| Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. | Q53888400 | ||
| Reply to: “Anti-TNF-induced autoimmune hepatitis” | Q58130529 | ||
| Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis | Q80022983 | ||
| Pathogenesis of autoimmune hepatitis | Q82680799 | ||
| Autoimmune hepatitis | Q82936688 | ||
| Successful treatment of autoimmune hepatitis with methotrexate | Q83217904 | ||
| Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience | Q84499955 | ||
| British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis | Q84561367 | ||
| EASL Clinical Practice Guidelines: Autoimmune hepatitis | Q86075911 | ||
| Anti-TNF-induced autoimmune hepatitis | Q87457230 | ||
| Use of sirolimus in the treatment of refractory autoimmune hepatitis | Q88185818 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunosuppressive drug | Q249619 |
| autoimmune hepatitis | Q786844 | ||
| hepatitis A | Q157661 | ||
| immunosuppression | Q1455316 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 22-26 | |
| P577 | publication date | 2017-03-01 | |
| 2017-03-14 | |||
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | The use of immunosuppression in autoimmune hepatitis: A current literature review | |
| P478 | volume | 23 |
Search more.